• Elevance Health reported an EPS of $11.97, surpassing estimates and indicating strong financial health.
• The company's revenue reached $48.77 billion, a 15.4% increase year-over-year, outperforming market expectations.
• Elevance Health has consistently exceeded analyst predictions, with a notable earnings surprise of 6.78% this quarter.

Elevance Health, trading under the symbol on the NYSE, is a prominent player in the healthcare sector. The company provides a range of health insurance products and services, competing with industry giants like UnitedHealth. On April 22, 2025, Elevance Health reported earnings per share (EPS) of $11.97, surpassing the estimated $11.41, showcasing its strong financial performance.

The company's revenue for the first quarter of 2025 reached $48.77 billion, exceeding the estimated $46.30 billion. This represents a 15.4% increase from the same period last year, highlighting Elevance Health's growth trajectory. The revenue figure also surpassed the Zacks Consensus Estimate of $46.03 billion by 5.95%, demonstrating the company's ability to outperform market expectations.

Elevance Health's EPS of $11.97 marks a significant improvement from the $10.64 reported in the same quarter last year. The earnings surprise for this quarter stands at 6.78%, indicating the company's consistent ability to exceed analyst predictions. Over the past four quarters, Elevance Health has outperformed consensus EPS estimates three times, reinforcing its strong financial standing.

Despite a sector-wide selloff triggered by UnitedHealth's decision to lower its full-year forecast, Elevance Health has reaffirmed its forecast for 2025. This move indicates the company's confidence in its financial outlook and its resilience in the face of industry challenges. The company's price-to-earnings (P/E) ratio of approximately 15.85 reflects the market's valuation of its earnings, while its price-to-sales ratio of about 0.53 suggests a favorable market value relative to its sales.

Elevance Health's financial metrics further underscore its robust performance. The enterprise value to sales ratio is around 0.66, and the enterprise value to operating cash flow ratio is approximately 20.19, indicating the company's efficiency in generating cash from operations. With a debt-to-equity ratio of approximately 0.76 and a current ratio of around 2.01, Elevance Health demonstrates a balanced approach to financial leverage and liquidity management.